CASP1 and Alzheimer disease: Thus, both animal and clinical studies have demonstrated the vital role of NLRP3 inflammasome in the pathogenesis of AD, and strategies targeting the NLRP3-caspase-1 pathway are currently being explored to find treatments for AD (230–233).